-
NAV$104.02
as of April 14, 2026 -
YTD RETURNS1.70%
as of April 14, 2026 -
Total Net Assets$1.03B
as of April 14, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
About PPH
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Overview
Why PPH
- Highly Liquid Companies: Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
- Industry Leaders: Index methodology favors the largest companies in the industry
- Global Scope: Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
Performance
Fees
Holdings
Portfolio
Sector Weightings (%) as at 31 Mar 2026
-
Sector
% of Net Assets -
Health Care
99.66 -
Other/Cash
0.34
Country Weightings (%) as at 31 Mar 2026
-
Country
% of Net Assets -
United States
61.19 -
United Kingdom
12.19 -
Switzerland
10.76 -
Denmark
4.81 -
France
4.73 -
Japan
3.15 -
Israel
2.83 -
Other/Cash
0.34